TXG Positive Sentiment Score: 85/100
10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
Wednesday, March 13, 2024 2 min read
Key Takeaway: 10x Genomics has commenced commercial shipments of its new GEM-X products, including the Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. This next-generation technology architecture is designed to improve performance and reduce costs for researchers. The company anticipates that these advancements will significantly enhance single cell analysis capabilities.
Full Press Release Details
The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost
PLEASANTON, Calif.,March 13, 2024/PRNewswire/ --10x Genomics, Inc.(Nasdaq:TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3.GEM-Xis the next generation of the company's leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability.
"It's been incredible to see the enthusiasm from customers since we first announced the GEM-X architecture last month, and we can't wait to get these new products in researchers' hands," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer of 10x Genomics. "GEM-X sets a new standard for single cell analysis and gives customers important performance advantages that will immediately benefit their research. This is one of multiple steps we have planned to make single cell more accessible for all."
GEM-X is exclusively available for use on Chromium X Series instruments and delivers important performance and workflow advantages, including:
"Selecting the optimal assay for single-cell experiments is challenging. However, it's evident that identifying more genes per cell enriches our understanding of cellular functions and the intricacies of biology," said Luciano Martelotto, Associate Professor at the University ofAdelaide. "GEM-X, with its exceptional transcript capture, can enhance our capacity to differentiate cell types, spot rare cells and decode regulatory pathways. Improved accuracy in transcriptome data further facilitates the seamless integration of single-cell findings from diverse research projects and platforms."
About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit10xgenomics.comor connect with us onLinkedInorX (Twitter).
Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product launches, performance, configuration, costs, capabilities, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
Disclosure Information10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
ContactsInvestors:[email protected]Media:[email protected]